Bio-Techne

TECH

Market cap $10.1B

MINNEAPOLIS , Nov. 25, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: 8th Annual Evercore Healthcare Conference 2025 December 2, 2025 8:20 AM EST Citi's 2025 Global Healthcare Conference December 3, 2025 3:15 PM EST 53rd Annual Nasdaq Investor Conference December 9, 2025 9:30 AM GMT A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar. About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities.

Bio-Techne Corporation ( TECH ) Jefferies London Healthcare Conference 2025 November 20, 2025 7:30 AM EST Company Participants James Hippel - Executive VP of Finance & CFO Conference Call Participants Tycho Peterson Tycho Peterson Presentation Tycho Peterson Okay. Great. We're going to kick it off.

Bio-Techne Corporation ( TECH ) Stephens Annual Investment Conference 2025 November 18, 2025 9:00 AM EST Company Participants James Hippel - Executive VP of Finance & CFO William Geist - President of Protein Sciences Segment Conference Call Participants Steven Etoch - Stephens Inc., Research Division Presentation Steven Etoch Stephens Inc., Research Division [Audio Gap] Is intended to be more of a fireside chat, so I'll stop along the way and poll for any questions. So feel free to chime in as needed.

Partnership strengthens Bio-Techne's leadership in AI-enabled protein innovation NovoBody™ Duo molecules offer multi-specific binding capabilities for advanced research and diagnostics Collaboration aligns with Bio-Techne's strategic growth pillars and megatrends in precision medicine MINNEAPOLIS and SEATTLE , Nov. 18, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced a licensing agreement with Monod Bio, a Seattle-based biotechnology company spun out from the Nobel Prize-winning David Baker lab at the University of Washington, Institute for Protein Design. The agreement grants Bio-Techne exclusive commercial rights to a specific subset of Monod's NovoBody™ Duo molecules, a new class of AI-designed bispecific binding proteins.

Bio-Techne Corporation ( TECH ) Stifel 2025 Healthcare Conference November 11, 2025 9:20 AM EST Company Participants Kim Kelderman - CEO, President & Director James Hippel - Executive VP of Finance & CFO Conference Call Participants Daniel Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Daniel Arias Stifel, Nicolaus & Company, Incorporated, Research Division Okay. We'll go ahead and get started.

Bio-Techne Corporation ( TECH ) UBS Global Healthcare Conference 2025 November 10, 2025 10:15 AM EST Company Participants Kim Kelderman - CEO, President & Director James Hippel - Executive VP of Finance & CFO Conference Call Participants Daniel Leonard - UBS Investment Bank, Research Division Presentation Daniel Leonard UBS Investment Bank, Research Division Our next session here is the management team from Bio-Techne. We're lucky to be joined by Kim Kelderman, Jim Hippel and Dave Clair.

MINNEAPOLIS , Nov. 6, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: UBS Global Healthcare Conference 2025 November 10, 2025 10:15 AM EST Stifel 2025 Healthcare Conference November 11, 2025 9:20 AM EST Stephens Investment Conference November 18, 2025 8:00 AM CST Jefferies Global Healthcare Conference November 20, 2025 12:30 PM GMT A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar. About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities.

Bio-Techne Corporation ( TECH ) Q1 2026 Earnings Call November 5, 2025 9:00 AM EST Company Participants David Clair - VP of Investor Relations & Corporate Development Kim Kelderman - CEO, President & Director James Hippel - Executive VP of Finance & CFO Conference Call Participants Daniel Leonard - UBS Investment Bank, Research Division Matthew Larew - William Blair & Company L.L.C., Research Division Puneet Souda - Leerink Partners LLC, Research Division Patrick Donnelly - Citigroup Inc., Research Division Daniel Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Kyle Boucher - TD Cowen, Research Division Catherine Ramsey - Robert W.

Bio-Techne's Q1 earnings meet expectations, but revenues slip 1%, sending shares lower despite stronger margins.

While the top- and bottom-line numbers for Techne (TECH) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.